SelectScience
Join Free
Accelerating Science
NewsLife Sciences

SeraNovo enters license agreement with Carna Biosciences to develop an oral formulation of Carna’s kinase inhibitor

SeraNovo
27 May 2020
Tom Casburn
Associate Editor

Industry news

SeraNovo has announced that it has signed a second license agreement with Carna Biosciences, Inc., a company engaged in the drug development of kinase inhibitors. Under the agreement, the companies will expand their existing collaboration and jointly develop an oral formulation of a new active ingredient with an enhanced bioavailability.

Utilizing its proprietary Deep Eutectic Solvent (DES) formulation platform, SeraNovo is formulating one of Carna’s proprietary drugs to increase its oral bioavailability. The DES formulation platform is based on GRAS excipients that are used for oral administration and broadly used in the industry.

Niall Hodgins, CEO of SeraNovo commented: “After our initial license announcement in October 2019, we are pleased to extend our relationship with Carna to include the formulation of another promising active ingredient. This expansion of our partnership with an industry leader is a great development towards widespread adoption of our breakthrough formulation technology.”

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>

Links

SeraNovoCompany website

Tags

ProteomicsProteomics is the systemic bioinformatics study of proteins and amino acids, including their structure, size, function and identification. Tools used in proteomics include chromatography, blotting and gels, protein arrays, mass spectrometry and ELISA and associated analysis software. Analyzers and proteomic systems should be sensitive, high resolution, fast and may be automated for high-throughput.Drug DeliveryDrug Delivery refers to dosage form, route of administration, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect. Drug delivery is often approached via the biopharmaceutical or small molecule drug's formulation, but it may also involve medical devices or drug-device combination products. Considerations include instrumentation, software and services. Bioprocessing / FermentationBioprocessing is the use of biological materials to perform commercial, scientific or medical research processes. Biological materials used include cells, enzymes and organisms. Usually bioprocessing requires a batch or continuous bioreactor such as a fermentor or cell culture system. The advantages of using a reactor include high productivity, easy configuration, adjustable values and automation.KinasesFormulationFormulation is the process of combining active pharmaceutical ingredients with excipients to produce a drug which is both stable and active.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.

Related articles